Hecht Beth 4

What Happened

• Beth Hecht, Chief Legal Officer and Corporate Secretary of Xeris Biopharma (XERS), sold 16,667 shares in an open‑market transaction on April 1, 2026.
• The weighted average sale price was $5.99 per share, for total proceeds of approximately $99,859. This was a sale (not a purchase), which is often routine insider selling.

Key Details

• Transaction date: 2026-04-01. Weighted average price reported: $5.99. Total value: ~$99,859.
• Price range: shares were sold in multiple transactions at prices between $5.890 and $6.085 (inclusive). The filer says they can provide a breakdown of shares sold at each price on request.
• Transaction effected pursuant to a Rule 10b5-1 trading plan (footnote).
• Shares owned after the transaction: not specified in the provided Form 4 data.
• Filing: Form 4 filed 2026-04-03 (two days after the transaction), which appears to be timely under the SEC’s 2-business-day reporting rule.

Context

• The sale was executed under a pre-established 10b5-1 plan, which allows insiders to trade according to a pre-set schedule and is generally treated as routine. This filing is informational; it does not indicate management’s view of the company’s near-term prospects.